Condition
Hip Necrosis
Total Trials
6
Recruiting
0
Active
4
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Active Not Recruiting4
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04993638Active Not Recruiting
Post Market Clinical Follow-up of Dual-mobility Acetabular Cup EUROSCUP MOBILE
NCT05142462Active Not Recruiting
Post Market Clinical Follow-up of EUROSCUP Fixe Acetabular Cup
NCT04995822Active Not Recruiting
Post Market Clinical Follow-up of EUROSTEM Femoral Stem
NCT03326804Active Not Recruiting
H1 Hip Resurfacing Arthroplasty
NCT04210440Not ApplicableCompletedPrimary
The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression
NCT02114489Phase 3Terminated
Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis
Showing all 6 trials